GlassScriptPhysician profile
Michael M Mccaffrey
NPI 1902863103
$35,771.59
in general payments reported to CMS, 2019-2025
44 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $22K · 2021: $353 · 2022: $743 · 2023: $444 · 2024: $348 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.30 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,996.19 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $15,831.41 | 2019-2023 | Austedo Xr |
| Abbvie INC. | $1,070.85 | 2021-2025 | |
| Ucb, INC. | $352.33 | 2019-2025 | Briviact, Bimzelx |
| Novartis Pharmaceuticals Corporation | $208.29 | 2019-2022 | |
| Biogen, INC. | $196.32 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $162.08 | 2019-2024 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $160.50 | 2019-2020 | |
| Lilly USA, LLC | $149.65 | 2019-2023 | Reyvow, Emgality |
| Avanir Pharmaceuticals, INC. | $116.12 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $102.25 | 2019-2022 | |
| Genzyme Corporation | $102.14 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $86.26 | 2019-2020 | |
| Livanova USA, INC. | $81.91 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Kyowa Kirin, INC. | $77.82 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccaffrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.